[go: up one dir, main page]

TW200716605A - 2,6-quinolinyl derivatives, processes for preparing them and their uses - Google Patents

2,6-quinolinyl derivatives, processes for preparing them and their uses

Info

Publication number
TW200716605A
TW200716605A TW095119798A TW95119798A TW200716605A TW 200716605 A TW200716605 A TW 200716605A TW 095119798 A TW095119798 A TW 095119798A TW 95119798 A TW95119798 A TW 95119798A TW 200716605 A TW200716605 A TW 200716605A
Authority
TW
Taiwan
Prior art keywords
preparing
processes
quinolinyl derivatives
quinolinyl
derivatives
Prior art date
Application number
TW095119798A
Other languages
English (en)
Inventor
Benjamin Perry
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0511781A external-priority patent/GB0511781D0/en
Priority claimed from GB0600213A external-priority patent/GB0600213D0/en
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of TW200716605A publication Critical patent/TW200716605A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095119798A 2005-06-09 2006-06-05 2,6-quinolinyl derivatives, processes for preparing them and their uses TW200716605A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0511781A GB0511781D0 (en) 2005-06-09 2005-06-09 2,6-quinolinyl derivatives, processes for preparing them and their uses
US20615805A 2005-08-18 2005-08-18
GB0600213A GB0600213D0 (en) 2006-01-06 2006-01-06 2,6-quinolinyl derivatives, processes for preparing them and their uses

Publications (1)

Publication Number Publication Date
TW200716605A true TW200716605A (en) 2007-05-01

Family

ID=36968449

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095119798A TW200716605A (en) 2005-06-09 2006-06-05 2,6-quinolinyl derivatives, processes for preparing them and their uses

Country Status (19)

Country Link
US (1) US7732614B2 (zh)
EP (1) EP1902045B1 (zh)
JP (1) JP2008542407A (zh)
KR (1) KR20080021085A (zh)
AR (1) AR054129A1 (zh)
AT (1) ATE496041T1 (zh)
AU (1) AU2006254772B2 (zh)
BR (1) BRPI0611243A2 (zh)
CA (1) CA2610800A1 (zh)
DE (1) DE602006019731D1 (zh)
EA (1) EA013080B1 (zh)
IL (1) IL187235A0 (zh)
MX (1) MX2007014721A (zh)
MY (1) MY140739A (zh)
NO (1) NO20080125L (zh)
NZ (1) NZ563739A (zh)
PE (1) PE20070081A1 (zh)
TW (1) TW200716605A (zh)
WO (1) WO2006131200A1 (zh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003232472B2 (en) 2002-04-30 2008-09-18 Ucb Pharma 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
US20090202527A1 (en) * 2004-11-19 2009-08-13 Biogen Idec Ma Inc. Treatment for multiple sclerosis
WO2006131200A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament
WO2008125215A1 (en) * 2007-04-12 2008-10-23 Ucb Pharma, S.A. Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
CA2758548A1 (en) * 2009-04-17 2010-10-21 Biogen Idec Ma Inc. Compositions and methods to treat acute myelogenous leukemia
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
MY160723A (en) * 2013-12-30 2017-03-15 Univ Putra Malaysia An anticoagulant
USD812958S1 (en) 2016-06-08 2018-03-20 Samsung Electronics Co., Ltd. Cooktop
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
TWI856956B (zh) 2018-04-12 2024-10-01 美商莫菲克醫療股份有限公司 人類整合素α４β７拮抗劑
WO2019236417A1 (en) 2018-06-04 2019-12-12 Biogen Ma Inc. Anti-vla-4 antibodies having reduced effector function
IL282545B2 (en) * 2018-10-30 2025-04-01 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
WO2020092383A1 (en) * 2018-10-30 2020-05-07 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) * 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
KR102908219B1 (ko) 2019-08-14 2026-01-08 길리애드 사이언시즈, 인코포레이티드 알파 4 베타 7 인테그린의 저해용 화합물
KR20220102669A (ko) 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 인간 인테그린 α4β7의 억제
WO2025106410A1 (en) * 2023-11-15 2025-05-22 Dice Molecules Sv, Inc. Alpha 4 beta 7 integrin modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69528197T2 (de) 1994-12-14 2003-06-05 Santen Pharmaceutical Co., Ltd Neue 1,3-dialkylharnstoff-derivate
DE69824183T2 (de) 1997-08-22 2005-04-21 Hoffmann La Roche N-alkanoylphenylalaninderivate
HUP0104766A3 (en) 1998-08-26 2002-08-28 Aventis Pharma Ltd West Mallin Aza-bicycles which modulate the inhibition of cell adhesion and medicaments containing them
CZ20013832A3 (cs) 1999-04-28 2002-04-17 Dr. Reddy's Research Foundation Substituované bicyklické heterocyklické sloučeniny, způsob jejich přípravy a jejich pouľití jako antiobezitních a hypocholesterolemických činidel
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
AU2003232472B2 (en) * 2002-04-30 2008-09-18 Ucb Pharma 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
GB0329584D0 (en) 2003-12-20 2004-01-28 Tanabe Seiyaku Co Novel compounds
WO2006131200A1 (en) 2005-06-09 2006-12-14 Ucb Pharma, S.A. 2,6 quinolinyl derivatives, processes for preparing them and their use as medicament

Also Published As

Publication number Publication date
WO2006131200A1 (en) 2006-12-14
US7732614B2 (en) 2010-06-08
JP2008542407A (ja) 2008-11-27
US20070004775A1 (en) 2007-01-04
AU2006254772B2 (en) 2011-06-02
EA013080B1 (ru) 2010-02-26
AU2006254772A1 (en) 2006-12-14
NZ563739A (en) 2009-12-24
CA2610800A1 (en) 2006-12-14
PE20070081A1 (es) 2007-02-15
DE602006019731D1 (de) 2011-03-03
ATE496041T1 (de) 2011-02-15
AR054129A1 (es) 2007-06-06
IL187235A0 (en) 2008-02-09
MX2007014721A (es) 2008-02-14
KR20080021085A (ko) 2008-03-06
EP1902045B1 (en) 2011-01-19
NO20080125L (no) 2008-01-08
MY140739A (en) 2010-01-15
EP1902045A1 (en) 2008-03-26
EA200702589A1 (ru) 2008-06-30
BRPI0611243A2 (pt) 2010-08-24

Similar Documents

Publication Publication Date Title
TWI268278B (en) 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses
JO2578B1 (en) Compounds Theophene benzimidazole
EP2308867A3 (en) 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
TW200608973A (en) Rapamycin polymorph Ⅱ and uses thereof
TW200800999A (en) Novel compounds
WO2007067506A3 (en) 2-pyrimidinyl pyrazolopyridine erbb kinase inhibitors
WO2004074244A3 (en) Pyrimidine compounds
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
TW200612892A (en) Novel compounds
IL188861A0 (en) 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them
DE602004024213D1 (en) Aminopropanolderivate
IL176142A0 (en) Processes for preparing montelukast sodium
ZA200604410B (en) Imidazole derivatives, processes for preparing them and their uses
TW200738659A (en) Novel compounds
TW200638930A (en) Acetylene derivatives
WO2007065595A3 (en) Xanthine derivatives, processes for preparing them and their uses
TWI315305B (en) Piperidin-4-yl-amide derivatives,pharmaceutical compositions comprising the same,process for preparing the same and the use thereof
GB0508314D0 (en) Organic compounds
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2007065684A3 (en) Bicyclic heteroyclic compounds as antiinflammatory or antiallergic agents
SG151306A1 (en) Novel benzothiazoles and the use thereof as medicaments
WO2008070354A3 (en) 5- and 6- substituted benzimidazole thiophene compounds
WO2008138591A3 (en) Bicyclic and heterobicyclic derivatives,processes for preparing them and their uses